title: Effect of OKT3 in steroid-resistant renal transplant rejection.
abstract: Between January 1, 1982, and November 1, 1986, 169 cadaver renal graft transplantations were performed at this hospital with CsA as induction therapy. OKT3 was not available in this period. Of these grafts, 15.9% were lost within 6 months, 10.7% from acute rejection (AR). Between November 1, 1986, and October 1, 1992, 483 cadaver renal graft transplantation were performed. Induction therapy included CsA and OKT3 was available. Of these grafts, 8.7% were lost inside 6 months, 3.1% from AR. Of these last 483 grafts, 113 received 125 courses of OKT3. Ten courses were prophylactic, and 115 courses in 103 patients were for rejection resistant to steroid therapy (biopsy proven in all but 2 cases. Ninety-three percent of rejection episodes treated with OKT3 responded, at least initially. Graft survival in OKT3-treated patients was 81%, 77%, and 76% at 6 months, 1 year, and 2 years, respectively. In contrast, graft survival in steroid-resistant rejection during the first period (without OKT3) was 59%, 57%, and 57% at these intervals. There were 8 infective deaths within 6 months in the 113 OKT3-treated patients, compared with 2 in the 343 who did not receive OKT3 (P < 0.001). There were 7 viral deaths in the OKT3 group compared with none in those not receiving OKT3 (P < 0.001). Prophylaxis with oral acyclovir and cotrimoxazole was instituted in October 1990 in OKT3-treated patients and ganciclovir use was increased. Since this change, no further viral deaths have occurred. OKT3 is a very effective antirejection agent, but its use is associated with an increased mortality from viral infections. With appropriate prophylaxis and treatment, however, this mortality can be reduced.
authors.affiliation: Renal Transplant Unit, Princess Alexandra Hospital, Woolloongabba, Brisbane, Australia.
authors.forename: J J
authors.initials: JJ
authors.lastname: Petrie
authors.forename: R J
authors.initials: RJ
authors.lastname: Rigby
authors.forename: C M
authors.initials: CM
authors.lastname: Hawley
authors.forename: M G
authors.initials: MG
authors.lastname: Suranyi
authors.forename: M
authors.initials: M
authors.lastname: Whitby
authors.forename: D
authors.initials: D
authors.lastname: Wall
authors.forename: I R
authors.initials: IR
authors.lastname: Hardie
mesh_terms: D016572:Cyclosporine / Q000008:administration & dosage*; D004347:Drug Interactions; D004351:Drug Resistance; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D016853:Muromonab-CD3 / Q000494:pharmacology*; D013256:Steroids / Q000627:therapeutic use
chemical_list: D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine